Skip to main content
R

RNA4Tx

Inactive

RNA4Tx provides a continuous‑flow platform for manufacturing RNA therapeutics that eliminates double‑stranded RNA (dsRNA) impurities at the source, removing the need for costly post‑synthesis purification. The fluidics‑based system runs long manufacturing batches, boosting RNA yields per DNA template and lowering production costs. It scales from high‑volume therapeutic manufacturing to small‑scale, personalized RNA treatments, supporting a broadening portfolio of RNA products.

Worcester, MassachusettsFounded 20224300+ followers
Updated 1 month ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

RNA therapeutics often contain double‑stranded RNA (dsRNA) contaminants generated during synthesis, which require expensive and inefficient post‑production purification steps. These purification requirements increase manufacturing costs and limit scalability, especially for personalized or high‑volume treatments.

Solution

RNA4Tx offers a continuous‑flow manufacturing platform that produces RNA molecules while preventing dsRNA formation from the start. The fluidic system runs long, uninterrupted batches, delivering higher RNA yields per DNA template and eliminating the need for downstream purification. By integrating three decades of process expertise, the platform reduces material waste and lowers overall production costs. Its modular design can be scaled to support both large‑volume commercial drug manufacturing and small‑batch personalized therapies, accelerating development timelines for a broad spectrum of RNA‑based products.

Target Audience

Primary customers are pharmaceutical manufacturers and biotech companies developing RNA‑based therapeutics, including both large‑scale commercial producers and organizations focused on personalized medicine.

Features

  • Continuous‑flow reactor architecture that synthesizes RNA without generating dsRNA impurities
  • Extended run capability that increases RNA yield per DNA template, improving material efficiency
  • Elimination of post‑synthesis purification steps, reducing processing time and cost
  • Scalable fluidics infrastructure adaptable for high‑volume manufacturing or low‑volume personalized batches
  • Integrated process monitoring to maintain product purity and consistency across scale
This profile is AI-generated and may contain inaccuracies.